SynthesisTargeted oncology2025

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

Aleksandra Wieczorek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.